)
Viridian Therapeutics (VRDN) investor relations material
Viridian Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Lumvoa generated $24.7M in Q3 2026 net product revenue, its first launch quarter; more than 100 patients had started therapy by September 30.
Q3 net loss was $101.2M, compared with $34.6M a year earlier; cash, cash equivalents and marketable securities totaled $955.2M at quarter-end.
Pipeline priorities include elegrobart, VRDN-008 and VRDN-292, with milestones expected through Q4 2026 and Q1 2027.
Financial highlights
Q3 total revenue was $25.8M versus $70.6M a year earlier; the prior-year period included a one-time $70.0M Kissei upfront license payment.
Q3 operating expenses were $129.2M, including $70.1M R&D and $57.6M SG&A; operating loss was $103.5M.
Q3 net loss was $101.2M versus $34.6M; 9M net loss was $333.2M versus $222.2M.
9M revenue was $26.2M versus $70.7M; 9M R&D was $219.3M versus $249.7M, while SG&A was $151.3M versus $61.6M.
Q3 R&D fell to $70.1M from $86.3M, while SG&A rose to $57.6M from $24.3M, reflecting lower late-stage study costs and commercial launch investment.
Outlook and guidance
Elegrobart BLA submission for TED remains on track for Q1 2027; planned delivery, if approved, is via an at-home autoinjector with subcutaneous Q4W or Q8W dosing.
VRDN-008 Phase 1 data and FcRn portfolio development plans are expected in Q4 2026; VRDN-292 Phase 1 initiation in Graves’ disease patients is also planned for Q4.
Existing cash and anticipated Lumvoa revenue, plus potential elegrobart revenue if approved, are expected to fund current plans through profitability; September 30 liquidity was $955.2M.
Broad Lumvoa payer coverage remains a target within six to nine months of launch; a permanent J-code takes effect January 1, 2027.
A veligrotug MAA was submitted to the EMA in January 2026; review and approval timing remains subject to regulatory uncertainty.
- Strong Lumvoa IV launch and pipeline progress position for TED market expansion and leadership.VRDN
Wells Fargo 21st Annual Healthcare Conference - FDA approval and strong cash reserves drive commercial and pipeline momentum in TED.VRDN
Q2 2026 - Advancing toward BLA filing with strong phase 3 data, breakthrough status, and launch readiness.VRDN
Goldman Sachs 46th Annual Global Healthcare Conference - Lumvoa and elegrobart drive innovation in TED, with a robust pipeline for autoimmune expansion.VRDN
Company presentation - FDA approves Lumvoa for all forms of TED, offering rapid, durable relief and immediate access.VRDN
FDA announcement - Approval expected June 30, with launch-ready teams and strong clinical differentiation.VRDN
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Ready for TED drug launch in 2026, aiming for broad access and major market expansion.VRDN
Jefferies Global Healthcare Conference 2026 - Veligrotug and elegrobart show strong efficacy in TED, with launch readiness and financial strength.VRDN
Corporate presentation - Significant efficacy and safety in chronic TED support a 2027 BLA for a subcutaneous autoinjector.VRDN
Study result
Next Viridian Therapeutics earnings date
Next Viridian Therapeutics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)